Ryoji Takazawa

18PUBLICATIONS
40CO-AUTHORS
Litigation, adjudication and dispute resolutionPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Toxicology (incl. clinical toxicology)Wastewater treatment processes
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Sep 14, 2026
Stone-Event-Free Survival After Ureteroscopic Lithotripsy According to Residual Fragment Size: Zero Residual Fragment Indicates a Good Prognosis.

|May 12, 2026
Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA Study.

|Apr 11, 2026
Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First-Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real-World Study (YUSHIMA Study).

Rie Muta, Hiroshi Fukushima, Hajime Tanaka

|Mar 19, 2026
Real-World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Propensity-Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis.

Yosuke Yasuda, Soichiro Yoshida, Shugo Yajima

|Dec 22, 2025
Clinical Features and Risk Factors of Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study (YUSHIMA Study).

Takahiko Soma, Hajime Tanaka, Yuki Nakamura

|Jun 17, 2025
Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study.

Yosuke Yasuda, Noboru Numao, Shunya Matsumoto

Pageof 3

Frequent Collaborators

8 joint publications

Hajime Tanaka

6 joint publications

Yuma Waseda

5 joint publications

Yasuhisa Fujii

4 joint publications

Soichiro Yoshida